Precigen Inc (Nasdaq: PGEN), biopharmaceutical company that specialises in the development of innovative gene and cell therapies, announced on Monday that it has completed the rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for PRGN-2012 (zopapogene imadenovec†), an investigational gene therapy for adults with recurrent respiratory papillomatosis (RRP). The submission includes a request for priority review, which, if granted, would shorten the review timeline from 10 to 6 months.
PRGN-2012 is designed to trigger immune responses against cells infected by human papillomavirus (HPV) types 6 and 11, the primary causes of RRP. The therapy has the potential to become the first FDA-approved treatment for this rare and life-threatening condition, which currently relies on repeated surgeries that do not address the underlying viral infection.
The BLA is backed by data from a Phase 1/2 pivotal trial (NCT04724980) involving 38 adult RRP patients. In the study, more than 50% of patients achieved a complete response, defined as no RRP surgeries within 12 months after treatment, while over 85% saw a reduction in surgical interventions compared to the prior year. The therapy was well-tolerated, with no dose-limiting toxicities or treatment-related adverse events exceeding Grade 2.
PRGN-2012 received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation from the European Commission. The BLA submission is part of an accelerated approval pathway, reflecting the urgent need for new treatment options for RRP patients.
Precigen's AdenoVerse platform, which underpins PRGN-2012, leverages proprietary adenovectors for efficient gene delivery. The company believes its platform's superior performance characteristics could offer a competitive edge in treating complex diseases.
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
ANGLE plc reports successful dual CTC-DNA and ctDNA analysis using Illumina platform
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Vast Therapeutics receives USD2m grant from National Institutes of Health
Nanobiotix reports first patient dosed in Phase 2 lung cancer study
AstraZeneca's Datroway approved in US for HR-positive breast cancer
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
bioAffinity Technologies declares successful beta launch of CyPath Lung in Texas